CTLA4 and lymphoma: Combined inhibition of PD1 or PD-L1- and CTLA4-mediated suppression of anti-lymphoma immunity seems supported by the finding that CTLA4 significantly increased during treatment with nivolumab and ipilmumab and remained so after the stop of treatment with this drug (Figure 2, lane e).